Bladder Cancer

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. July 24, 2026

BCG at Home: A First-in-kind Trial of Home-based Intravesical Bacillus Calmette-Guérin Delivery for High-risk Non-muscle-invasive Bladder Cancer. July 24, 2026

Postoperative Management After Pathological Complete Response to Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: An Exploratory Reconstructed Individual Patient Data Analysis. July 23, 2026

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. July 22, 2026

Bladder Preservation Therapy in Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. July 22, 2026

VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification. July 21, 2026

Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract. July 20, 2026

Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract July 17, 2026

Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. July 17, 2026

Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression. July 16, 2026

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials. July 24, 2026

Impact of age on the effectiveness of intravesical Bacillus Calmette‑Guérin and gemcitabine/docetaxel in treatment-naïve high-risk non‑muscle‑invasive bladder cancer. July 23, 2026

Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer. July 23, 2026

Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications. July 22, 2026

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial. July 21, 2026

Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC). July 20, 2026

A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer. July 20, 2026

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update. July 17, 2026

Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes. July 17, 2026

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer. July 16, 2026

Page 1 of 607